Shelton Capital Management Biomarin Pharmaceutical Inc Transaction History

Shelton Capital Management

$3.85 Billion
Q3 2024

A detailed history of Shelton Capital Management transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Shelton Capital Management holds 7,453 shares of BMRN stock, worth $496,593. This represents 0.01% of its overall portfolio holdings.

Number of Shares

7,453

Previous 7,601 1.95%

Holding current value

$496,593

Previous $625,000 16.32%

% of portfolio

0.01%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $10,214 - $13,888	-148 Reduced 1.95%	7,453 $523,000
Q2 2024 Aug 13, 2024	BUY	$74.43 - $92.22 $565,742 - $700,964	7,601 New	7,601 $625,000
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $958,379 - $1.19 Million	-13,199 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$71.37 - $96.85 $14,987 - $20,338	-210 Reduced 1.57%	13,199 $1.12 Million
Q4 2019 Feb 11, 2020	SELL	$64.27 - $86.37 $122,112 - $164,103	-1,900 Reduced 12.41%	13,409 $1.13 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $1.12 Million - $1.31 Million	13,949 Added 1025.66%	15,309 $1.31 Million
Q1 2019 May 10, 2019	SELL	$84.2 - $98.62 $1.17 Million - $1.38 Million	-13,949 Reduced 91.12%	1,360 $15.3 Million
Q2 2018 Aug 10, 2018	BUY	$76.01 - $99.03 $235,022 - $306,200	3,092 Added 25.31%	15,309 $1.44 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-10,626 Closed	0 $0
Q1 2017 Nov 28, 2017	BUY	N/A	1,677 Added 18.74%	10,626 $933,000
Q3 2016 Dec 06, 2017	BUY	N/A	8,949 New	8,949 $828,000
Q3 2016 Dec 04, 2017	BUY	N/A	8,949	8,949 $741,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Shelton Capital Management with notifications on news.

Account

Shelton Capital Management Biomarin Pharmaceutical Inc Transaction History